Literature DB >> 22834461

Differential executive functioning performance by phase of bipolar disorder.

Kelly A Ryan1, Aaron C Vederman, E Michelle McFadden, Anne L Weldon, Masoud Kamali, Scott A Langenecker, Melvin G McInnis.   

Abstract

OBJECTIVE: This study examined the influence of illness phase on executive functioning performance using factor-derived cognitive scores in a cross-sectional design.
METHODS: Healthy control (HC) subjects (n = 57), and euthymic (E-BD) (n = 117), depressed (D-BD) (n = 73), and hypomanic/mixed (HM/M-BD) (n = 26) patients with bipolar disorder (BD) were evaluated using executive functioning measures (Wisconsin Card Sorting Test, Trail Making Test-Parts A and B, Verbal Fluency, Parametric Go/No-Go, Stroop, and Digit Symbol) comprising Conceptual Reasoning and Set-Shifting (CRSS), Processing Speed with Interference Resolution (PSIR), Verbal Fluency and Processing Speed (VFPS), and Inhibitory Control (IC) factor scores.
RESULTS: Two of the four executive functioning factors were significantly different between groups based upon phase of illness. The HM/M group was significantly worse than both of the other BD groups and the HC group in IC. The VFPS factor was sensitive to the active phase of BD, with the HM/M-BD and D-BD groups worse than HC. Extending our prior work, the PSIR factor, and now the CRSS factor were significantly worse in BD relative to HC, irrespective of phase of illness.
CONCLUSIONS: Phase of illness had differential cognitive profiles in executive functioning factors, even after considering and excluding the impact of clinical features, illness characteristics, medications, and demographics. Consolidating executive functioning tasks into reliable factor scores provides unique information to measure and define cognitive deficiencies throughout phases of BD, and to measure intermediate phenotypes in BD, and may aid in tracking and clarifying treatment focus.
© 2012 John Wiley and Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22834461      PMCID: PMC3773478          DOI: 10.1111/j.1399-5618.2012.01032.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  30 in total

1.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

2.  Effect of symptoms on executive function in bipolar illness.

Authors:  T Dixon; E Kravariti; C Frith; R M Murray; P K McGuire
Journal:  Psychol Med       Date:  2004-07       Impact factor: 7.723

3.  Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study.

Authors:  W G van Gorp; L Altshuler; D C Theberge; J Wilkins; W Dixon
Journal:  Arch Gen Psychiatry       Date:  1998-01

4.  Neuropsychological impairment among manic, depressed, and mixed-episode inpatients with bipolar disorder.

Authors:  Michael R Basso; Natasha Lowery; Jackie Neel; Rod Purdie; Robert A Bornstein
Journal:  Neuropsychology       Date:  2002-01       Impact factor: 3.295

5.  Elevated striatal and decreased dorsolateral prefrontal cortical activity in response to emotional stimuli in euthymic bipolar disorder: no associations with psychotropic medication load.

Authors:  Stefanie Hassel; Jorge Rc Almeida; Natalie Kerr; Sharon Nau; Cecile D Ladouceur; Kate Fissell; David J Kupfer; Mary L Phillips
Journal:  Bipolar Disord       Date:  2008-12       Impact factor: 6.744

Review 6.  The effects of lithium on cognition: an updated review.

Authors:  Arlin K Pachet; Amy M Wisniewski
Journal:  Psychopharmacology (Berl)       Date:  2003-09-19       Impact factor: 4.530

7.  A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state.

Authors:  Matthew M Kurtz; Raphael T Gerraty
Journal:  Neuropsychology       Date:  2009-09       Impact factor: 3.295

8.  Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives.

Authors:  Emre Bora; Murat Yucel; Christos Pantelis
Journal:  J Affect Disord       Date:  2008-08-05       Impact factor: 4.839

9.  Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder.

Authors:  Anabel Martínez-Arán; Eduard Vieta; María Reinares; Francesc Colom; Carla Torrent; Jose Sánchez-Moreno; Antonio Benabarre; José Manuel Goikolea; Mercè Comes; Manel Salamero
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

10.  The sensitivity and psychometric properties of a brief computer-based cognitive screening battery in a depression clinic.

Authors:  Scott A Langenecker; Angela F Caveney; Bruno Giordani; Elizabeth A Young; Kristy A Nielson; Lisa J Rapport; Linas A Bieliauskas; Matthew J Mordhorst; Sheila Marcus; Naomi Yodkovik; Kevin Kerber; Stanley Berent; Jon-Kar Zubieta
Journal:  Psychiatry Res       Date:  2007-04-19       Impact factor: 3.222

View more
  25 in total

1.  Developing Dimensional, Pandiagnostic Inhibitory Control Constructs With Self-Report and Neuropsychological Data.

Authors:  Natania A Crane; Alvaro Vergés; Masoud Kamali; Runa Bhaumik; Kelly A Ryan; David F Marshall; Erika F H Saunders; Michelle T Kassel; Anne L Weldon; Melvin G McInnis; Scott A Langenecker
Journal:  Assessment       Date:  2018-02-06

2.  Cognitive deficits in first-degree relatives of bipolar patients: the use of homogeneous subgroups in the search of cognitive endophenotypes.

Authors:  Julia Volkert; J Haubner; J Kazmaier; F Glaser; J Kopf; S Kittel-Schneider; A Reif
Journal:  J Neural Transm (Vienna)       Date:  2016-06-08       Impact factor: 3.575

3.  Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study.

Authors:  Isabelle E Bauer; Austin Ouyang; Benson Mwangi; Marsal Sanches; Giovana B Zunta-Soares; Richard S E Keefe; Hao Huang; Jair C Soares
Journal:  J Psychiatr Res       Date:  2015-02-07       Impact factor: 4.791

4.  Domain-specific impairment in cognitive control among remitted youth with a history of major depression.

Authors:  Amy T Peters; Rachel H Jacobs; Natania A Crane; Kelly A Ryan; Sara L Weisenbach; Olusola Ajilore; Melissa Lamar; Michelle T Kassel; Laura B Gabriel; Amy E West; Jon-Kar Zubieta; Scott A Langenecker
Journal:  Early Interv Psychiatry       Date:  2015-07-14       Impact factor: 2.732

5.  Shared dimensions of performance and activation dysfunction in cognitive control in females with mood disorders.

Authors:  Kelly A Ryan; Erica L Dawson; Michelle T Kassel; Anne L Weldon; David F Marshall; Kortni K Meyers; Laura B Gabriel; Aaron C Vederman; Sara L Weisenbach; Melvin G McInnis; Jon-Kar Zubieta; Scott A Langenecker
Journal:  Brain       Date:  2015-03-28       Impact factor: 13.501

6.  Current Neural and Behavioral Dimensional Constructs across Mood Disorders.

Authors:  Scott A Langenecker; Rachel H Jacobs; Alessandra M Passarotti
Journal:  Curr Behav Neurosci Rep       Date:  2014-09-01

7.  Equivalent linear change in cognition between individuals with bipolar disorder and healthy controls over 5 years.

Authors:  Kelly A Ryan; Shervin Assari; Kaley Angers; David F Marshall; Kristin Hinrichs; Rebecca Easter; Pallavi Babu; Bethany D Pester; Scott A Langenecker; Melvin G McInnis
Journal:  Bipolar Disord       Date:  2017-09-14       Impact factor: 6.744

8.  Cognitive deficits in bipolar disorder: from acute episode to remission.

Authors:  J Volkert; M A Schiele; Julia Kazmaier; Friederike Glaser; K C Zierhut; J Kopf; S Kittel-Schneider; A Reif
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-26       Impact factor: 5.270

Review 9.  Neuroprogression and Cognitive Functioning in Bipolar Disorder: A Systematic Review.

Authors:  Taiane Cardoso; Isabelle E Bauer; Thomas D Meyer; Flavio Kapczinski; Jair C Soares
Journal:  Curr Psychiatry Rep       Date:  2015-09       Impact factor: 5.285

10.  Factor structure, construct validity, and age- and education-based normative data for the Parametric Go/No-Go Test.

Authors:  Kristen L Votruba; Scott A Langenecker
Journal:  J Clin Exp Neuropsychol       Date:  2013-01-07       Impact factor: 2.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.